Description

Eterna Peptides presents premium-grade Tirzepatide (GLP-2 Architecture) lyophilized powder, supplied in an advanced laboratory configuration of four (4) single-dose vials per kit. Tirzepatide is a pioneering, synthetically structured 39-amino-acid peptide analogue that functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Modeled directly after the endogenous GIP sequence, it features a custom C20 fatty diacid moiety that facilitates stable albumin binding to drastically extend its metabolic research half-life. Available in comprehensive kit mass configurations ranging from 10mg to 60mg, this multi-vial presentation serves as an elite investigative tool for tracking synergistic incretin receptor co-agonist pathways, cellular nutrient repartitioning, and metabolic rate adaptation.

### Available Kit Configurations (4 Vials Per Kit)
* **10mg Total Kit:** Delivering 4 precisely standardized 2.5mg single-dose vials. Calibrated for early-stage baseline metabolic exposure screens.
* **20mg Total Kit:** Delivering 4 precisely standardized 5.0mg single-dose vials. Standardized for mid-tier longitudinal tracking protocols.
* **30mg Total Kit:** Delivering 4 precisely standardized 7.5mg single-dose vials. Engineered for advanced cell-saturation metabolic modeling.
* **40mg Total Kit:** Delivering 4 precisely standardized 10.0mg single-dose vials. Calibrated for high-saturation dose-response assays.
* **50mg Total Kit:** Delivering 4 precisely standardized 12.5mg single-dose vials. Optimized for intensive structural signaling protocols.
* **60mg Total Kit:** Delivering 4 precisely standardized 15.0mg single-dose vials. Ultra-concentrated presentation for extended multi-subject trials.

### Mechanism of Action
Tirzepatide operates via a unique dual-agonist architecture that yields superior metabolic signaling compared to isolated GLP-1 mono-therapies:
* **Synergistic Incretin Receptor Signaling:** Tirzepatide binds with high affinity to both native GIP and GLP-1 receptors. It acts as a full agonist at the GIP receptor network and a biased agonist at the GLP-1 receptor path, driving efficient intracellular cyclic AMP ($cAMP$) accumulation to study optimal pancreatic beta-cell insulin secretion dynamics.
* **Hypothalamic Satiety Alignment:** The structural configuration effectively crosses blood-brain barrier boundaries to interface with pro-opiomelanocortin (POMC) and neuropeptide Y (NPY) neurons in the arcuate nucleus, signaling a down-regulation of food-seeking behaviors and appetite drive pathways.
* **Delayed Gastric Emptying Kinetics:** In metabolic stress models, Tirzepatide is monitored for its capacity to decelerate upper gastrointestinal motility, extending nutrient contact times to study localized satiety feedback loops.
* **Adipose Tissue Browning Regulation:** Via its powerful GIP receptor pathway activity, Tirzepatide is actively investigated for its ability to increase metabolic rate via white adipose tissue repartitioning, tissue-specific insulin sensitivity improvements, and enhanced systemic lipid oxidation ($ \beta\text{-oxidation} $).

### Research Applications
In preclinical and in vitro laboratory models, Tirzepatide 4-vial single-dose kits are utilized to investigate:
* High-velocity lipid mobilization, adipose tissue browning kinetics, and chronic obesity resistance pathways.
* Pancreatic beta-cell protection, glucose-dependent insulin transcription, and type-2 diabetes cellular models.
* Central nervous system satiety pathways, arcuate nucleus neuroplasticity, and behavioral food-seeking motivation curves.
* The comparative efficiency, baseline half-life, and multi-receptor affinity curves of dual GIP/GLP-1 co-agonists.

Our Tirzepatide vials undergo strict laboratory stabilization, vacuum-drying, and high-purity purification guidelines to ensure absolute peptide chain integrity, rapid reconstitution kinetics, and dependable experimental reproducibility across all individual single-dose vials.

—
*Disclaimer: This product is sold strictly for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic purposes.*